Abbott To Maintain Agreements With Cambridge Antibody Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott developed its RA therapy Humira and anti-interleukin-12 fully human monoclonal antibody using CAT technology.
You may also be interested in...
AstraZeneca Will Get Humira Royalty Revenue Through CAT Deal
AstraZeneca's acquisition of Cambridge Antibody Technology will give the firm royalty revenues from human monoclonal antibody technologies already licensed out by CAT, including Abbott's rheumatoid arthritis therapy Humira (adalimumab)
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency